Fluorine 18 MNI 1020

Drug Profile

Fluorine 18 MNI 1020

Alternative Names: [18F]JNJ 64326067; [18F]MNI-1020

Latest Information Update: 08 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Research & Development
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 08 Aug 2017 Janssen Research & Development plans a phase 0 trial for Alzheimer's disease (Diagnosis) in USA in August 2017 (NCT03239561)
  • 02 Aug 2017 Preclinical trials in Alzheimer's disease (Diagnosis) in USA (IV), before August 2017 (NCT03239561)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top